Literature DB >> 19944484

Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma.

Rachel H Gormley1, Stephen D Hess, Dipti Anand, Jacqueline Junkins-Hopkins, Alain H Rook, Ellen J Kim.   

Abstract

Cutaneous T-cell lymphomas most commonly have a CD4(+) memory T-cell phenotype with relatively indolent course, but may in rare cases present with a CD8(+) cytotoxic phenotype exhibiting strikingly more aggressive clinical behavior. We present two cases of the clinically aggressive subtype of primary cutaneous epidermotropic CD8(+) cutaneous T-cell lymphoma and review the current literature, clinical behavior, and recommendations for treatment distinct from that of more common CD4(+) variants of cutaneous T-cell lymphoma. Copyright (c) 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19944484     DOI: 10.1016/j.jaad.2009.02.035

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  10 in total

1.  Synergistic enhancement of cellular immune responses by the novel Toll receptor 7/8 agonist 3M-007 and interferon-γ: implications for therapy of cutaneous T-cell lymphoma.

Authors:  Maria Wysocka; Noor Dawany; Bernice Benoit; Andrew V Kossenkov; Andrea B Troxel; Joel M Gelfand; Michael Kelly Sell; Louise C Showe; Alain H Rook
Journal:  Leuk Lymphoma       Date:  2011-10

Review 2.  Managing Patients with Cutaneous B-Cell and T-Cell Lymphomas Other Than Mycosis Fungoides.

Authors:  Meenal Kheterpal; Neha Mehta-Shah; Pooja Virmani; Patricia L Myskowski; Alison Moskowitz; Steven M Horwitz
Journal:  Curr Hematol Malig Rep       Date:  2016-06       Impact factor: 3.952

3.  Primary cutaneous aggressive epidermotropic CD8 + T-cell lymphoma on upper eyelid.

Authors:  Joon Lee; You Jin Yang; Jung-In Kim; Ji-Hye Park; Won-Serk Kim
Journal:  Indian J Ophthalmol       Date:  2015-01       Impact factor: 1.848

4.  Primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphomas: reappraisal of a provisional entity in the 2016 WHO classification of cutaneous lymphomas.

Authors:  Joan Guitart; M Estela Martinez-Escala; Antonio Subtil; Madeleine Duvic; Melissa P Pulitzer; Elise A Olsen; Ellen Kim; Alain H Rook; Sara S Samimi; Gary S Wood; Michael Girardi; Jacqueline Junkins-Hopkins; Doina S Ivan; M Angelica Selim; Kimberly A Sable; Pooja Virmani; Laura B Pincus; Michael T Tetzlaff; Jinah Kim; Youn H Kim
Journal:  Mod Pathol       Date:  2017-01-27       Impact factor: 7.842

5.  Sudden aggravated CD8+ mycosis fungoides accompanied by hidden adenocarcinoma of the colon.

Authors:  Hye-Jin Ahn; Eun Jae Shin; Min-Jae Gwak; Ki-Heon Jeong; Min Kyung Shin
Journal:  JAAD Case Rep       Date:  2017-02-21

6.  Complete durable remission of a fulminant primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma after autologous and allogeneic hematopoietic stem cell transplantation.

Authors:  Kerasia-Maria Plachouri; Carsten Weishaupt; Dieter Metze; Georg Evers; Wolfgang E Berdel; Werner Kempf; Cord Sunderkötter; Matthias Stelljes
Journal:  JAAD Case Rep       Date:  2017-04-14

7.  Cutaneous CD8+ Cytotoxic T-Cell Lymphoma Infiltrates: Clinicopathological Correlation and Outcome of 35 Cases.

Authors:  Marion Wobser; Theresa Reinartz; Sabine Roth; Matthias Goebeler; Andreas Rosenwald; Eva Geissinger
Journal:  Oncol Ther       Date:  2016-08-18

8.  Nasolabial Ulcerated Placard Revealing a Primary Cutaneous Aggressive Epidermotropic CD8+ T-cell Lymphoma.

Authors:  J B Ntihebuwayo; F Hali; A Kerouach; H Rachadi; S Chiheb; F Marnissi
Journal:  Case Rep Dermatol Med       Date:  2022-08-09

Review 9.  Approach to Cutaneous Lymphoid Infiltrates: When to Consider Lymphoma?

Authors:  Yann Vincent Charli-Joseph; Michelle Gatica-Torres; Laura Beth Pincus
Journal:  Indian J Dermatol       Date:  2016 Jul-Aug       Impact factor: 1.494

10.  A Case of Primary Cutaneous Aggressive Epidermotropic CD8+ Cytotoxic T-Cell Lymphoma.

Authors:  Jungyoon Moon; Jong Seo Park; Kwang Hyun Cho
Journal:  Ann Dermatol       Date:  2018-02-21       Impact factor: 1.444

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.